Skip to main content

Table 3 Review of patient characteristics in published series of greater than ten patients of LARIAT LAAO

From: A review of the LARIAT device: insights from the cumulative clinical experience

Referenes

No. of patients with attempted ligation

No. of patients meeting clinical criteria screened

Mean age

Male (%)

AC Post-procedure

Mean/median CHADS2 Score/CHA2DS-VASC Scorea (Lip et al. 2010)

HAS-BLED Score (Lip et al. 2011)

Bartus et al. (2011)

12

14 screened, 2 excluded: 1 due to sub-optimal anatomy by pre-procedure CT, 1 due to presence of LAA thrombus by TEE at procedure onset

57.3

62

NR

NR

NR

Bartus et al. (2013)

92

119 screened, 27 excluded: 16 due to sub-optimal anatomy by pre-procedure CT, 11 due to mobile thrombus noted by TEE at time of procedure

62 ± 10

57

Warfarin if tolerated, else aspirin mono-therapy. 55 % treated with warfarin post-procedure

1.9 ± 0.95/2.8 ± 1.56

2.4 ± 1.1

Massumi et al. (2013)

20

NR

73 ± 8

65

65 % continued on Aspirin, 20 % on clopidogrel, 5 % on dual-antiplatelet therapy with Aspirin and dypyridamole, 15 % on warfarin, 5 % on rivaroxaban, 20 % on no AC

3.2 ± 1.2/4.8 ± 1.3

3.5 ± 1.0

Stone et al. (2013)

27

42 screened, 15 excluded; no further details

75 ± 8

74

Daily aspirin in all patients, dual anti-platelet therapy in 9 patients

3.5 ± 1.4/5.1 ± 1.5

4.6 ± 0.9

Price and Gibson (2014)

154

NR

72 ± 9

62

Aspirin mono-therapy 31 %, dual anti-platelet 24 %, oral AC 23 %, clopidogrel mono-therapy 7 %, aggrenox 0.6 %

2.8 ± 1.4/4.1 ± 1.6

3.2 ± 1.2

Miller et al. (2014)

41

NR

75 ± 10

46

At last follow-up, Aspirin 46 %, warfarin 20 %, Plavix 7 % dabigatran 7 %, rivaroxaban 7 %

3.0 ± 1.3

4.4 ± 1.4

  1. AC anti-coagulation, CT computed tomography scan, LAA left atrial appendage, TEE trans-esophageal echocardiography, NR not reported
  2. aMedians are presented with an interval, means are presented with a standard deviation